

ACED PATIENT ADVOCATE SESSION 2022 PROGRAMME

13 DECEMBER 17:00 - 19:00 GMT / 09:00 - 11:00 PST





CONTENTS

WELCOME


- 3 WELCOME
- 4 JOINING INSTRUCTIONS
- 6 CHAIR AND SPEAKER BIOGRAPHIES
- 7 FULL AGENDA

The International Alliance for Cancer Early Detection (ACED) proudly presents its first symposium on patient advocacy in research. We hope this session will provide an opportunity to learn from patient advocates and experienced researchers how the involvement of patients and the public advocates can improve both the quality and relevance of research, and can help researchers to better understand and articulate the benefits their work can have for cancer patients.

During this online session, we will hear from Dr. Christian Von Wagner on the importance of involving patients and the public in research and the benefit this brings.

This session will also feature Dr. Emma Woodward who will share how creating a patient forum with open questions can ensure research meets patients' needs and have beneficial outcomes to both researchers and participants.

We will hear from patients and patient advocate representatives about their contributions to ACED research studies, and how they envision working with researchers going forward.



The REPRESENT team will share about a Community Engagement Roadmap to Improve Participant Representation in Cancer Research Early Detection and evidence-based best practice for patient and public involvement in research.

Finally, the panel discussion will focus on patients' experience of being involved with research and tips for researchers for best practices to collaborate with patients and the public to co-develop research.

JOINING INSTRUCTIONS

ZOOM LINK

Please register for the event on Eventbrite. On the day of the event, you will receive an email from Eventbrite containing the Zoom link and the passcode.

If you have any issues accessing the event, please contact us at ACED@cancer.org.uk.

ZOOM ETIQUETTE

To reduce background noise, please ensure you join the meeting with your microphone muted.

There will be time at the end of each session for questions, so please either raise your virtual hand and turn your camera on, or enter your question into the meeting chat.





CHAIR AND SPEAKER **BIOGRAPHIES**

We are delighted to welcome experts from a wide range of disciplines, institutions and backgrounds to speak, debate and chair at our Patient Advocate Session.

Read more about our confirmed Chairs and Speakers.



Prof. Robert Bristow The University of Manchester, UK

Professor Rob Bristow is the Director of the Manchester Cancer Research Centre (MCRC), a unique partnership between Cancer Research UK, The University of Manchester, and the Christie NHS Foundation Trust. Professor Bristow is also the Manchester Director for ACED and a senior group leader in Translational Oncogenomics at the CRUK Manchester Institute. His primary research interests are in tumour hypoxia, DNA damage signalling and repair in tumours, and the genomics of prostate cancer progression and cancer treatment response.



Prof. Rebecca Fitzgerald University of Cambridge, UK

Rebecca Fitzgerald is a Professor of Cancer Prevention at the University of Cambridge and Director of the CRUK Cambridge Centre Early Detection Institute. She still practices medicine as an Honorary Consultant in Gastroenterology at Addenbrooke's Hospital, Cambridge. The focus of her research group is to improve methods for early detection of oesophageal cancer through better understanding of the molecular pathogenesis. Rebecca was awarded the prestigious Westminster medal and prize for her first proof-of-concept work on the Cytosponge[™] and associated assays for diagnosing Barrett's oesophagus in 2004.



Dr. Christian von Wagner University College London, UK

Dr Christian von Wagner is a Reader in Behavioural Research of Early Diagnosis of Cancer at the Health Behaviour Research Centre, UCL. He is working on research into the social and psychological determinants of uptake of the NHS Bowel Cancer Screening Programme. His other research interests patient experience of bowel cancer screening and diagnostic tests. His other research interests include patient decision making and preferences, health literacy and cancer communication.

Dr. Emma Woodward The University of Manchester, UK

Dr Emma Woodward is an ACED Director of Research for Trials and Principle Investigator of the ACED-funded study: ELECTRIC (Early Detection of Hereditary Renal Cancer). Dr Woodward's current research is aimed at improving early detection in families with inherited cancer predisposition.

Dr. Jackilen Shannon Oregon Health & Science University, US

Dr. Shannon is a Professor in the Division of Oncologic Sciences, Associate Director of Community Outreach and Engagement at the Knight Cancer Institute and Associate Director at OHSU's Oregon Clinical and Translational Research Institute. Her research program has focused for nearly 20 years on environmental and behavioral risk factors for cancer and implementation of interventions or clinical trials in cancer prevention. Dr. Shannon's work has more recently expanded to focus on community engagement and education and ensuring application of cancer research to the community. In this role, she has developed a formal mechanism for working collaboratively with community groups and hospital systems across Oregon to bring the power of academic research to community level decision-making.



Dr. Ignacia Arteaga The University of Cambridge, UK

Dr Ignacia Arteaga is a postdoctoral research fellow in the Department of Social Anthropology at the University of Cambridge. Dr Arteaga is currently the lead on the "REPRESENT: A Community Engagement Roadmap to Improve Participant Representation in Cancer Research Early Detection" ACED pilot with Prof. Shannon (OHSU), Prof. Pashayan (UCL), and Dr Starling (MFT). She is also a Research Fellow in Robinson College.

AGENDA **TUESDAY 13 DECEMBER**

INTRODUCTION

PROF. REBECCA FITZGERALD, UNIVERSITY OF CAMBRIDGE, UK (17:05 GMT / 09:05 PST)

KEYNOTE SPEECH

DR. CHRISTIAN VON WAGNER, UNIVERSITY COLLEGE LONDON, UK (17:10 GMT / 09:10 PST)

ELECTRIC: EARLY DETECTION OF HEREDITARY RENAL CANCER DR. EMMA WOODWARD, THE UNIVERSITY OF MANCHESTER, UK (17:30 GMT / 09:30 PST)

PATIENT AND PATIENT ADVOCATE INTRODUCTIONS PATIENT ADVOCATE FROM THE UK PATIENT ADVOCATE FROM THE US (17:45 GMT / 09:45 PST)

REPRESENT: A COMMUNITY ENGAGEMENT ROADMAP TO IMPROVE PARTICIPANT REPRESENTATION IN CANCER RESEARCH EARLY DETECTION DR. IGNACIA ARTEAGA, UNIVERSITY OF CAMBRIDGE, UK DR. JACKILEN SHANNON, OREGON HEALTH & SCIENCE UNIVERSITY, US (17:55 GMT / 09:55 PST)

PANEL DISCUSSION CHAIR; PROF. ROBERT BRISTOW, THE UNIVERSITY OF MANCHESTER, UK (18:10 GMT / 10:10 PST)

PANEL MEMBERS: PROF. REBECCA FITZGERALD, UK DR. JACKILEN SHANNON, US DR. IGNACIA ARTEAGA, UK

CLOSING REMARKS PROF. REBECCA FITZGERALD, UNIVERSITY OF CAMBRIDGE, UK (18:30 GMT / 10:30 PST)

ACED PATIENT ADVOCATE SESSION 2022 PROGRAMME

DR. CHRISTIAN VON WAGNER, UK DR. EMMA WOODWARD, UK UK AND US PATIENT ADVOCATES









≜UC





The University of Manchester